United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA).

ABSTRACT: Gamma-amino butyric acid (GABA) is marketed in the U.S. as a dietary supplement. USP conducted a comprehensive safety evaluation of GABA by assessing clinical studies, adverse event information, and toxicology data. Clinical studies investigated the effect of pure GABA as a dietary supplement or as a natural constituent of fermented milk or soy matrices. Data showed no serious adverse events associated with GABA at intakes up to 18 g/d for 4 days and in longer studies at intakes of 120 mg/d for 12 weeks. Some studies showed that GABA was associated with a transient and moderate drop in blood pressure (<10% change). No studies were available on effects of GABA during pregnancy and lactation, and no case reports or spontaneous adverse events associated with GABA were found. Chronic administr

SUBMITTER: Oketch-Rabah HA 

PROVIDER: S-EPMC8399837 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature